BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

31 related articles for article (PubMed ID: 38423634)

  • 1. Fisetin is a senotherapeutic that extends health and lifespan.
    Yousefzadeh MJ; Zhu Y; McGowan SJ; Angelini L; Fuhrmann-Stroissnigg H; Xu M; Ling YY; Melos KI; Pirtskhalava T; Inman CL; McGuckian C; Wade EA; Kato JI; Grassi D; Wentworth M; Burd CE; Arriaga EA; Ladiges WL; Tchkonia T; Kirkland JL; Robbins PD; Niedernhofer LJ
    EBioMedicine; 2018 Oct; 36():18-28. PubMed ID: 30279143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fisetin nanoparticles based on cells cycle and apoptosis intervention for the treatment of lymphoma and leukemia.
    Yang T; Gou H; Lin T; Yang Y; Jin X; Dong T; Zhang Y; Chen X
    Int J Pharm; 2024 Apr; 654():123971. PubMed ID: 38452832
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fisetin and/or capecitabine causes changes in apoptosis pathways in capecitabine-resistant colorectal cancer cell lines.
    Zehra K; Banu A; Can E; Hülya C
    Naunyn Schmiedebergs Arch Pharmacol; 2024 May; ():. PubMed ID: 38748229
    [TBL] [Abstract][Full Text] [Related]  

  • 4. How fisetin reduces the impact of age and disease on CNS function.
    Maher P
    Front Biosci (Schol Ed); 2015 Jun; 7(1):58-82. PubMed ID: 25961687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fisetin from Dietary Supplement to a Drug Candidate: An Assessment of Potential.
    Mirza MA; Padhi S; Mohapatra S; Mahmood S; Iqbal Z
    Curr Pharm Biotechnol; 2024 Apr; ():. PubMed ID: 38716552
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Therapeutic Potential and Molecular Mechanisms of the Multitargeted Flavonoid Fisetin.
    Rauf A; Abu-Izneid T; Imran M; Hemeg HA; Bashir K; Aljohani ASM; Aljohani MSM; Alhumaydhi FA; Khan IN; Bin Emran T; Gondal TA; Nath N; Ahmad I; Thiruvengadam M
    Curr Top Med Chem; 2023; 23(21):2075-2096. PubMed ID: 37431899
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cytotoxic and Senolytic Effects of Methadone in Combination with Temozolomide in Glioblastoma Cells.
    Kaina B; Beltzig L; Piee-Staffa A; Haas B
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32977591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are There Thresholds in Glioblastoma Cell Death Responses Triggered by Temozolomide?
    He Y; Kaina B
    Int J Mol Sci; 2019 Mar; 20(7):. PubMed ID: 30925722
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Abrogation of Cellular Senescence Induced by Temozolomide in Glioblastoma Cells: Search for Senolytics.
    Beltzig L; Christmann M; Kaina B
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010664
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fisetin induces DNA double-strand break and interferes with the repair of radiation-induced damage to radiosensitize triple negative breast cancer cells.
    Khozooei S; Lettau K; Barletta F; Jost T; Rebholz S; Veerappan S; Franz-Wachtel M; Macek B; Iliakis G; Distel LV; Zips D; Toulany M
    J Exp Clin Cancer Res; 2022 Aug; 41(1):256. PubMed ID: 35989353
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Artesunate in glioblastoma therapy: Case reports and review of clinical studies.
    Strik H; Efferth T; Kaina B
    Phytomedicine; 2024 Jan; 123():155274. PubMed ID: 38142662
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotoxic and Cytotoxic Activity of Fisetin on Glioblastoma Cells.
    Beltzig L; Christmann M; Dobreanu M; Kaina B
    Anticancer Res; 2024 Mar; 44(3):901-910. PubMed ID: 38423634
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fisetin, a Potent Anticancer Flavonol Exhibiting Cytotoxic Activity against Neoplastic Malignant Cells and Cancerous Conditions: A Scoping, Comprehensive Review.
    Kubina R; Krzykawski K; Kabała-Dzik A; Wojtyczka RD; Chodurek E; Dziedzic A
    Nutrients; 2022 Jun; 14(13):. PubMed ID: 35807785
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 15.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 16.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.